Abstract:Diabetes mellitus comprises a group of carbohydrate metabolism disorders that share a common main feature of chronic hyperglycemia that results from defects of insulin secretion, insulin action, or both. Insulin is an important anabolic hormone, and its deficiency leads to various metabolic abnormalities in proteins, lipids, and carbohydrates. Atherosclerosis develops as a result of a multistep process ultimately leading to cardiovascular disease associated with high morbidity and mortality. Alteration of lipid metabolism is a risk factor and characteristic feature of atherosclerosis. Possible links between the two chronic disorders depending on altered metabolic pathways have been investigated in numerous studies. It was shown that both types of diabetes mellitus can actually induce atherosclerosis development or further accelerate its progression. Elevated glucose level, dyslipidemia, and other metabolic alterations that accompany the disease development are tightly involved in the pathogenesis of atherosclerosis at almost every step of the atherogenic process. Chronic inflammation is currently considered as one of the key factors in atherosclerosis development and is present starting from the earliest stages of the pathology initiation. It may also be regarded as one of the possible links between atherosclerosis and diabetes mellitus. However, the data available so far do not allow for developing effective anti-inflammatory therapeutic strategies that would stop atherosclerotic lesion progression or induce lesion reduction. In this review, we summarize the main aspects of diabetes mellitus that possibly affect the atherogenic process and its relationship with chronic inflammation. We also discuss the established pathophysiological features that link atherosclerosis and diabetes mellitus, such as oxidative stress, altered protein kinase signaling, and the role of certain miRNA and epigenetic modifications.

Mechanisms and Treatment of Dyslipidemia in Diabetes

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Pharmacotherapy of dyslipidemia in type2 diabetics

Lipids and lipid management in diabetes

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Treatment of Dyslipidemia in Type 2 Diabetes

Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus

Modification of lipoprotein metabolism and function driving atherogenesis in diabetes

Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes

The mechanisms of glycolipid metabolism disorder on vascular injury in type 2 diabetes

Molecular Mechanisms and Clinical Insights

Hyperlipidemia and Cardiovascular Disease in People with Type 1 Diabetes: Review of Current Guidelines and Evidence

Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk

Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms

Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines

Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review

Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes

Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets

The current landscape for diabetes treatment: Preventing diabetes-associated CV risk

The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation